GCOR Genencor International, (MM)

Genencor Expands Its Presence in Russia PALO ALTO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Genencor International (NASDAQ:GCOR) today announced that it is strengthening its position in the Russian Federation by opening an office in Moscow, effective September 15, 2004. Genencor is offering customers in the Russian Federation an extensive portfolio of enzyme products for the cleaning, food, beverage, feed, pulp, paper and specialty industries. "We are very excited about establishing an office in Moscow, as we consider the Russian enzyme market to be extremely important in our strategy for further growth," says Aryan Moelker, vice president of market development for Genencor. "As we believe that the market in Russia will grow exponentially in the years to come, it's critical for us to have a local presence in the Federation. Furthermore, we believe this will allow us to improve our level of service to local customers." Head of the representative office, Liekel Faber, a 13-year employee of Genencor adds, "We are glad that the Russian Federation is focusing on innovative industries and technologies to enhance its economic development and growth. Biotech enzymes can contribute to this growth by making process industries more efficient and more sustainable. For example, our enzymes allow food and beverage manufacturers to improve the quality of their products, while at the same time lower their cost and impact on the environment." Genencor's new office address is: Genencor International Limited Entrance # 6; office # 717 12 Krasnopresnenkaya nab. Moscow Russia, 123610 Phone +7.095.258.1435 Fax +7.095.258.1436 About Genencor Genencor International is a diversified biotechnology company that develops and delivers innovative products and services into the health care, agri-processing, industrial and consumer markets. Using an integrated set of technology platforms, Genencor's products deliver innovative and sustainable solutions to improve the quality of life. Genencor traces its history to 1982 and has grown to become a leading biotechnology company, with over $380 million in year 2003 annual revenues. Genencor has principal offices in Palo Alto, California; Rochester, New York; and Leiden, the Netherlands. This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 . These include statements concerning plans, objectives, goals, strategies, future events or performance and all other statements which are other than statements of historical fact, including without limitation, statements containing words such as "believes," "anticipates," "expects," "estimates," "projects," "will," "may," "might" and words of a similar nature. Such statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Some important factors that could cause actual results to differ include dependence on the efforts of third parties; dependence on new and uncertain technology and its uncertain application to new business ventures; regulatory actions or delays, or uncertainties related to product development, testing or manufacturing; ability to form and maintain strategic alliances; dependence on certain intellectual property rights of both Genencor and third parties; the competitive nature of Genencor's industry; and risks of obsolescence of certain technology. These and other risk factors are more fully discussed in Genencor's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the United States Securities and Exchange Commission. The forward-looking statements contained in this release represent the judgment of Genencor as of the date of this press release. Genencor disclaims, however, any intent or obligation to update any forward-looking statements. DATASOURCE: Genencor International CONTACT: media: Francis Stalder, +31-6-29-09-36-38, or investors: Tom Rathjen, +1-650-846-7500, both of Genencor International Web site: http://www.genencor.com/

Copyright